Perrigo cough/cold sales grow 27% in 2nd quarter, contributing to 11% OTC sales gain.
This article was originally published in The Tan Sheet
Executive Summary
PERRIGO COUGH/COLD SALES RISE 27% IN THE SECOND QUARTER ended Dec. 31 because of a "much stronger" cough and cold season than last year, the company said Feb. 6. In the first half of fiscal 1996, cough/cold product sales were ahead 20%. In contrast, however, a "moderate" flu season as well as a "soft and competitive" market caused analgesic sales to drop "slightly" in the quarter, the Allegan, Mich.-based store-brand manufacturer noted
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.